{"name":"Celon Pharma SA","slug":"celon-pharma-sa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CPL500036 - high dose","genericName":"CPL500036 - high dose","slug":"cpl500036-high-dose","indication":"Type 2 diabetes","status":"phase_2"},{"name":"CPL207280","genericName":"CPL207280","slug":"cpl207280","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"CPL409116","genericName":"CPL409116","slug":"cpl409116","indication":"Other","status":"phase_2"},{"name":"CPL500036 - low dose","genericName":"CPL500036 - low dose","slug":"cpl500036-low-dose","indication":"Other","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Esketamine DPI - low dose","genericName":"Esketamine DPI - low dose","slug":"esketamine-dpi-low-dose","indication":"Treatment-resistant depression (Phase 2 investigation)","status":"phase_2"}]}],"pipeline":[{"name":"CPL500036 - high dose","genericName":"CPL500036 - high dose","slug":"cpl500036-high-dose","phase":"phase_2","mechanism":"CPL500036 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CPL207280","genericName":"CPL207280","slug":"cpl207280","phase":"phase_2","mechanism":"CPL207280 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CPL409116","genericName":"CPL409116","slug":"cpl409116","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CPL500036 - low dose","genericName":"CPL500036 - low dose","slug":"cpl500036-low-dose","phase":"phase_2","mechanism":"CPL500036 is a low-dose drug with an unknown existing mechanism.","indications":[],"catalyst":""},{"name":"Esketamine DPI - low dose","genericName":"Esketamine DPI - low dose","slug":"esketamine-dpi-low-dose","phase":"phase_2","mechanism":"Esketamine is an NMDA receptor antagonist that blocks glutamate signaling in the brain, with rapid-acting antidepressant effects.","indications":["Treatment-resistant depression (Phase 2 investigation)","Major depressive disorder with suicidal ideation (potential indication)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE54YnNObW12VVJWR3BkWkd4ZmZiZDhmaXRxS3VWNjByS0xuclRVX2dKZXdJVk1qX19DSWljWl9FNzJDcEUxVWk2REVYREtKNkNIa05kcHBR?oc=5","date":"2026-04-03","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Price Performance - Yahoo! Finance Canada","headline":"Price Performance - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE42b2dBMndUVU5WYXZIT21RUmM4TGdxWTRIOTFNX3VuVzNILUFtdEhvUDhFRTJXaEU2R0Q4U0ZPZy0wME12R1hycG5fOWZoUUxfVHVUX21rU2pwd0lYUFdhTGREN0U?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Celon Pharma SA (8RP.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Celon Pharma SA (8RP.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPMTBwTGktUHlrb2c3cjR6RXVKYVBTM3dLRkhLVUNYRDB4YzgtZkJQUWZsTl9JbWFQSGtyM2h4dGhKS0dZaDFqeGZmNVI3RkxYTkVUUTF2ZkltQzVyaFhfV1JPNWItcGZHZGsyQUo1S1FBOUFGMUZUaDlaSkUwZm9GWXhJUnBwYmlPb2NQZFhBRjBhTXdMQnVndEdtXy1YNXVsaFFNa1daaW1XTDdvemxKRUpLc3V0S1kxd0pUR2R3WmdzUHFzY3JzY2xRWUFxRGZkVDFTS0J2dw?oc=5","date":"2026-02-07","type":"patent","source":"lupin.com","summary":"Lupin and Celon Announce Strategic Development and Licensing Agreement for Generic Advair Diskusi® - lupin.com","headline":"Lupin and Celon Announce Strategic Development and Licensing Agreement for Generic Advair Diskusi®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOMjAza2QxcWxTLTVpQVViVFZwYWRqRkRTU0JGX0ZBTTJWek1EWDYtZkh6Y2pyeDV0dFlaMndZNzdkRWVkUmZFUUZ2dnlJdDlRclU0dlJoa0FlSjQwaW15Vk1Mb1pjRU5Nd2F3TklYOW56bDZVMzJIYVplVjFmZ3BGRkZZbl9tZE5xVGQ1eDY1MW1CU1R6ekFiNmFKMGZPQlRESFMyMFRWcnZFcWl0eHRFXzRxUzd0QzZzc1V6TEFteHk3MnM3TXZNd3U5UWhKYkE?oc=5","date":"2025-10-08","type":"regulatory","source":"globenewswire.com","summary":"FDA Clears Celon Pharma’s Schizophrenia Drug for Phase 3 Trial - globenewswire.com","headline":"FDA Clears Celon Pharma’s Schizophrenia Drug for Phase 3 Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOYVBkMmIySkpsRXZMV0VuSFY1MjFpVlV4Wm1ab21yOWRKZmN1M2lQZE5KbExLTGxraTJhMVhxU2VINjZMd1NzdFZyTHZ1SHZTdVljbU9GQjBkdGcydmlwdnNGU0lxT3lHdGNnWlZUVFFkTVZ6VzBHdHVVNXBtWV9zRWZUZlJXMV90VVp1RmFDSjVhbDAwVG50R2FWWUxVczFIQlRUbEJGdUE5cnpZUF9rMi1iUllsaUtqWDhncHlrOEdIZENVdlBNbVlUUVhwLVVPckZzQ1ZJb3JzdlZT?oc=5","date":"2025-07-24","type":"trial","source":"European Medical Journal","summary":"Dual JAK/ROCK Inhibition in Rheumatoid Arthritis: Results of a Phase II Study Of CPL’116 - European Medical Journal","headline":"Dual JAK/ROCK Inhibition in Rheumatoid Arthritis: Results of a Phase II Study Of CPL’116","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQUXR0WGhkWE8xdFJaaFBGXzc4Z2U1VTN2OS1zMFVTZUFHLURuSUZRSE9BR0tCbGZCMWhKOWZUVGQtRURtQkk2WF94YTJRbXp0T01SZmNlYU5rdWpYeWtrbVlvVWQwa04wQWJ4eWkxZnJUc0pqRFBSeFB3VncwVHJNZnJwZUFoelExWl9LYm13YlhfYmd5OTFDNUl2VW9ObmZmZ1Z2cktmYTkyZjY4Skk4YXV4Qk9IdFNr?oc=5","date":"2024-07-10","type":"trial","source":"World Pharmaceutical Frontiers","summary":"Celon Pharma’s CPL’36 yields positive results in Phase 2 schizophrenia trial - World Pharmaceutical Frontiers","headline":"Celon Pharma’s CPL’36 yields positive results in Phase 2 schizophrenia trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQejZuczZHMnlvanhaU3FydmgzWWl4QVN0WEYxc0hnd3lKdGU1MXBZaVd3R0xtYzNiYkt0Z2FNNW5YR1cyQmxvMDVEU3NCMUpicENhLW55czc1cmhveVhrdWhnMkNpaDdTVFQ3c2hxRzNPNHhQZGxYYTZVcjBCcWotZXFoazU1QkFYb2xKSl9heUtERl8yMm4yN2tB?oc=5","date":"2020-06-06","type":"pipeline","source":"openPR.com","summary":"Psychedelic Drugs Market 2020 to Grow at +16.3% CAGR by 2027 - openPR.com","headline":"Psychedelic Drugs Market 2020 to Grow at +16.3% CAGR by 2027","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2018-05-16","type":"patent","source":"firstpost.com","summary":"Glenmark Pharma pushes first generic product in Europe with asthma drug in Denmark - firstpost.com","headline":"Glenmark Pharma pushes first generic product in Europe with asthma drug in Denmark","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9qM0xOLTdUYlNhMUJ1am1yRGpHakVld2U2LWluTjZjQ0s5cENDa3ZSS1VyLXFRWGE1c3dJZVo2aGZ6bE1FdTZNLWRsenNxVzJndF8wOHZMUUExWmNjUGdNZ3lHNDVET3VXc3lDOHlZSHBxXzhqUTN4NDNaaEFZZ9IBgwFBVV95cUxOeGNjaXltb28zZEdyZXZkN0FWeEpjbnVVdDN6d3VwUmoweUdSR05GZEx5TkpQQXlDbjdvemxvRGpSZl95VG96QmhGakZzV3R3V0RKcGNIZ0VpYjBLUXZ5V2g3emZ6YV9OR3JoZmN4TFk2amhhaklOWnNsc0ZTY3VKeWJydw?oc=5","date":"2018-05-16","type":"pipeline","source":"Express Pharma","summary":"Glenmark Pharma launches Seretide Accuhaler - Express Pharma","headline":"Glenmark Pharma launches Seretide Accuhaler","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE40OUZtTlhtZ3NYSERCeWg5MG1CVFZrbVpuRWsya3R2cnhXV3VyTWpGRlBmN2VXZnQtWlJhMXdLSVd5cFVFM1lwNXhWaDRNRERWSy1fVnQtd0ZhdVB5bTlyM25jdEJPdw?oc=5","date":"2018-02-11","type":"pipeline","source":"TradingView","summary":"Technical Analysis of Celon Pharma SA (GPW:CLN) - TradingView","headline":"Technical Analysis of Celon Pharma SA (GPW:CLN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2015-10-23","type":"pipeline","source":"Business Standard","summary":"Glenmark inks licensing pact with Polish firm Celon for inhaler - Business Standard","headline":"Glenmark inks licensing pact with Polish firm Celon for inhaler","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":5},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}